Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Average Target Price from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $20.00.

ALT has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Thursday, November 14th. UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company.

Institutional Trading of Altimmune

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Altimmune by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after buying an additional 74,194 shares in the last quarter. Bellevue Group AG lifted its stake in Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after acquiring an additional 335,444 shares during the last quarter. BBR Partners LLC grew its stake in shares of Altimmune by 4.5% in the second quarter. BBR Partners LLC now owns 374,784 shares of the company’s stock worth $2,492,000 after acquiring an additional 16,271 shares during the period. Finally, SG Americas Securities LLC grew its stake in shares of Altimmune by 542.8% in the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after acquiring an additional 214,968 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 5.1 %

Shares of ALT stock opened at $9.03 on Friday. The business’s fifty day moving average is $7.71 and its 200 day moving average is $7.06. The stock has a market cap of $642.26 million, a price-to-earnings ratio of -5.83 and a beta of 0.15. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the business earned ($0.39) earnings per share. Equities research analysts expect that Altimmune will post -1.36 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.